Skip to content
orbyd

Dossier · WEST · Recently exited

WEST

LOW a7Defensive

Last analysed · · source: watchlist_research

Current thesis

Misclassified "AI-momentum" name — actually a money-losing B2B coffee roaster that [trade redacted] chasing RSI ~77 on sub-1x volume. No accelerating narrative now; only edge is a slow insider cluster + Benchmark $10 PT. Dead tape until Q2 (~Aug). SKIP / avoid re-entry until a clean higher-low reclaim above ~[entry redacted] on volume.

Invalidation trigger

No setup while it sits below a reclaimed $8.40 on sub-1x volume. Thesis fully dead if Q2 print (est. ~2026-08-06) shows revenue below the Q1 $308.8M run-rate or a widening EPS loss.

Thesis status

Open commitment scored if the trigger above fires How this is scored →

Current Thesis

The "small-cap-AI-momentum" tag this name carried was a misclassification — WEST is a B2B coffee/tea/extracts roaster with negative EPS, not an AI story. It [trade redacted] (entry [entry redacted] on 5/20, stop fill [entry redacted] on 5/26) after we chased it at RSI ~77 on sub-1x volume. The only real edge is a slow insider-buy cluster (8–10 buys/30d) plus Benchmark's $10 Buy PT (2026-05-11). Neither defends a broken structure. With Q1 already printed (2026-05-07) and Q2 not due until ~August, this is dead tape with no accelerating narrative. SKIP / avoid re-entry until it reclaims structure on volume.

Bull Case

  • Revenue beat, capacity ramp live: Q1 2026 (reported 2026-05-07) sales $308.8M beat the $285.2M consensus by +8.3% — the Conway, AR extract/ready-to-drink facility ramp is finally showing top-line. That is the actual narrative here, not AI.
  • Sell-side nudging up: Benchmark maintained Buy and raised its PT to $10 on 2026-05-11 — ~28% above the $7.79 exit print.
  • Insider conviction: 8–10 insider buys in a 30-day window (the orthogonal signal that originally flagged it) — management deploying personal capital into the capex-heavy turn.
  • Beverage-tape sympathy: WEST popped 2026-05-08 alongside Monster Beverage's +12.8% earnings move — it trades as a beverage/RTD beta when the group catches a bid.

Bear Case

  • Still loses money: Q1 EPS $(0.09) missed even the negative $(0.07) estimate — the revenue beat did not flow to the bottom line. Capex/debt from the Conway buildout is a drag.
  • Already had its pop and faded: Benzinga explicitly flagged WEST (2026-05-13) as overbought, high-RSI, in a "Risk Off Stocks That May Implode" piece — and it did fade straight into our stop.
  • Commodity exposure: elevated green-coffee input costs are a margin/pass-through risk for a roaster with thin profitability.
  • Thin sub-$10 micro: gaps through stops on any risk-off tick; sub-1x volume means no liquidity cushion. Insider buys are slow-burn and offer zero defense against near-term mean reversion.
  • No AI anything: the theme tag was regret-driven narrative confusion. There is no accelerating story to ride right now.

Setup & Price Structure

  • Last known print [entry redacted] (2026-05-26 stop/exit fill). No live price feed this cycle.
  • We entered [entry redacted] (5/20), [stop redacted] exited $7.79 — a -7.48% stop-out by construction: RSI 74–78 at entry with 0.79–0.89x volume on a thin micro.
  • Structure is broken: the overbought spike mean-reverted through the prior stop. Likely below the 20-EMA. No higher-low reclaim observed.
  • Benchmark PT $10 (2026-05-11) caps the realistic upside swing; the relevant level to watch is a reclaim of ~[entry redacted] (our old entry / pre-fade pivot) on >1x volume before any setup exists again.

Catalyst Calendar (next 30 days)

  • No binary catalyst within 30 days (window 2026-06-04 → 2026-07-04). Q1 already reported 2026-05-07.
  • Next earnings: Q2 2026 est. ~2026-08-06 (Q1 was 2026-05-07) — well outside the window. This is the next real datapoint and it is the thesis test, not a near-term trade.
  • No scheduled FDA/analyst-day/index events known. Conference appearances, if any, are non-binary.

What Would Change Our Mind

  • A higher-low reclaim above ~$8.40 on >1.5x volume with the beverage/RTD group bid — a fresh clean setup, not a re-buy of the broken one.
  • Q2 print (~2026-08-06) showing Conway-driven revenue acceleration above the Q1 $308.8M run-rate with EPS loss narrowing toward breakeven — that would convert the capex story into a real legacy-to-RTD pivot (archetype 4) worth a probe.
  • A genuine catalyst cluster (multiple PT raises in 14d) confirming sell-side is catching up to the ramp rather than one lone Benchmark note.

Correlation Notes

  • Trades as a beverage/RTD/consumer-staples beta, not AI — sympathy moves with Monster (MNST), Celsius, ADM and the staples complex (co-flagged with ADM in the 2026-05-13 overbought screen).
  • Input-cost correlation to green coffee (KC futures) — rising commodity = margin headwind.
  • Negatively correlated with risk-off rotations despite the "staples" label, because it's an unprofitable thin micro that gaps on liquidity withdrawal — it behaves like a small-cap risk asset, not a defensive.